The
Report PharmaPoint: Multiple Myeloma - Global Drug Forecast and
Market Analysis to 2023 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
The
Multiple Myeloma (MM) market is currently dominated by Velcade and
Revlimid, and the market is set to undergo substantial growth between
2013 and 2023. The main drivers of growth will be the launch of
monoclonal antibodies (mAbs) Empliciti and daratumumab, which will
not only provide a new treatment option for MM patients, but will
also lengthen the time between relapses, meaning that the duration of
Revlimid and/or Velcade treatments will also be longer. Furthermore,
the relatively mild safety profile of these mAbs and the significant
efficacies demonstrated by these agents will mean that more MM
patients will ultimately receive drug treatment. Label extensions of
these mAbs, as well as of second-generation proteasome inhibitors
ixazomib and Kyprolis, will further increase treatment options for
these patients. The biggest constrainers of the MM market are the
increasing cost-consciousness of healthcare providers, as the launch
and subsequent label extensions of these pipeline agents will lead to
a significant expense, which may impact uptake of these drugs. The
patent expiries of Revlimid and Velcade will somewhat alleviate
healthcare spending on multiple myeloma patients, which may assist in
the uptake of mAbs and second-generation PIs in the multiple myeloma
market.
View
Repor At :http://www.marketresearchreports.biz/analysis/556452
Highlights
Key
Questions Answered
-
The multiple myeloma market is marked by the presence of a number of
unmet needs. What are the main unmet needs in this market? Will the
drugs under development fulfil the unmet needs of multiple myeloma
market?
-
The late-stage multiple myeloma pipeline has therapies targeting
different multiple myeloma populations. Which late-stage drugs will
have the biggest impact in each patient population? Which of these
drugs will have the highest peak sales at the highest CAGR, and why?
-
The current multiple myeloma market is dominated by Velcade and
Revlimid. How will the advent of new mAbs change the drug treatment
landscape for multiple myeloma? How will the drug treatment rate
change over the next five years? What are the key drivers and
barriers to this change?
Key
Benefits
-
The main driver of the enormous expansion of the multiple myeloma
market will be the launch of mAbs Empliciti and daratumumab.
-
The second largest driver will be the label extension of currently
marketed drugs Kyprolis and Revlimid.
-
Another driver of the multiple myeloma market will be the ageing
population in the 8MM, which will increase the number of multiple
myeloma cases.
-
The increase in therapeutic options overall will lead to increases in
treatment rates in the 8MM. Also, as triplet/quadruplet therapies
increasingly become the standard of care within the forecast period,
this will increase the duration of treatment for each patient as well
as the number of treatments each patient receives.
Get
the Free Sample copy of this Report @
Scope
-
Overview of multiple myeloma, including epidemiology, etiology,
pathophysiology, symptoms, diagnosis, and treatment guidelines.
-
Annualized multiple myeloma therapeutics market revenue, average cost
of therapy and treatment usage pattern data from 2013 and forecast
for ten years to 2023.
-
Key topics covered include strategic competitor assessment, market
characterization, unmet needs, clinical trial mapping and
implications for the multiple myeloma therapeutics market.
-
Pipeline analysis: comprehensive data split across different phases,
emerging novel trends under development, and detailed analysis of
late-stage pipeline drugs.
-
Analysis of the current and future market competition in the global
multiple myeloma therapeutics market. Insightful review of the key
industry drivers, restraints and challenges. Each trend is
independently researched to provide qualitative analysis of its
implications.
Reasons to buy
The
report will enable you to -
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline. Additionally
a list of acquisition targets included in the pipeline product
company list.
-
Develop business strategies by understanding the trends shaping and
driving the global multiple myeloma therapeutics market.
-
Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the
global multiple myeloma therapeutics market in future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analysing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Track drug sales in the global multiple myeloma therapeutics market
from 2013-2023.
-
Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments and strategic partnerships.
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
Table
of Contents
1 Table of Contents
1 Table of Contents 11
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and
Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 27
3.2 Staging Systems 30
3.3 Response and Relapse
Criteria 31
3.4 Symptoms 33
3.5 Prognosis 34
3.6 Quality of Life 35
4 Epidemiology 38
4.1 Disease Background 38
4.2 Risk Factors and
Comorbidities 39
4.3 Global Trends 40
4.3.1 Incidence 40
4.3.2 Survival Rates for
Multiple Myeloma - 8MM 43
4.4 Forecast Methodology 44
4.4.1 Sources Used 46
4.4.2 Sources Not Used 48
4.4.3 Forecast Assumptions and
Methods, Multiple Myeloma Diagnosed Incident Cases 48
4.4.4 Forecast Assumptions and
Methods, Multiple Myeloma Five-Year Diagnosed Prevalent Cases 49
4.4.5 Forecast Assumptions and
Methods, Multiple Myeloma Clinical Stages at Diagnosis 50
4.5 Epidemiological Forecast
for Multiple Myeloma (2013-2023) 50
4.5.1 Diagnosed Incident Cases
of Multiple Myeloma 50
4.5.2 Age-Specific Diagnosed
Incident Cases of Multiple Myeloma 52
4.5.3 Sex-Specific Diagnosed
Incident Cases of Multiple Myeloma 54
4.5.4 Age-Standardized
Diagnosed Incidence of Multiple Myeloma 56
4.5.5 Diagnosed Incident Cases
of Multiple Myeloma by Clinical Stage at Diagnosis 57
4.5.6 Five-Year Diagnosed
Prevalent Cases of Multiple Myeloma 58
4.6 Discussion 60
4.6.1 Epidemiological Forecast
Insight 60
4.6.2 Limitations of the
Analysis 60
4.6.3 Strengths of the Analysis
61
5 Disease Management 62
5.1 Treatment Overview 62
5.2 Diagnosis 63
5.3 Clinical Practice 64
5.3.1 Primary Therapy for
SCT-Eligible Patients 65
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA:
Canada Toll Free: 866-997-4948
No comments:
Post a Comment